Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Efficacy and effectiveness of biologic therapy in inflammatory bowel disease. EFIFECT study].
Ginard D, Khorrami S, Pérez-Carazo L, Tavío-Hernández E, López-Sanromán A, García-Alvarado M, Muñoz F, Ibáñez-Samaniego L, Marín-Jiménez I, Guevara J, Casellas F. Ginard D, et al. Gastroenterol Hepatol. 2016 Jun-Jul;39(6):369-76. doi: 10.1016/j.gastrohep.2016.02.004. Epub 2016 Apr 20. Gastroenterol Hepatol. 2016. PMID: 27005800 Spanish.
Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease.
Taxonera C, Rodrigo L, Casellas F, Calvet X, Gómez-Camacho F, Ginard D, Castro M, Castro L, Ponce M, Martínez-Montiel P, Ricart E, Gisbert JP, López-San Román A, Morales JM, Casado MA. Taxonera C, et al. Among authors: ginard d. J Clin Gastroenterol. 2009 Nov-Dec;43(10):950-6. doi: 10.1097/MCG.0b013e3181986917. J Clin Gastroenterol. 2009. PMID: 19448569
Clinical outcome of newly diagnosed Crohn's disease: a comparative, retrospective study before and after infliximab availability.
Domènech E, Zabana Y, Garcia-Planella E, López San Román A, Nos P, Ginard D, Gordillo J, Martínez-Silva F, Beltrán B, Mañosa M, Cabré E, Gassull MA. Domènech E, et al. Among authors: ginard d. Aliment Pharmacol Ther. 2010 Jan 15;31(2):233-9. doi: 10.1111/j.1365-2036.2009.04170.x. Epub 2009 Oct 13. Aliment Pharmacol Ther. 2010. PMID: 19832727
[Psychology and inflammatory bowel disease].
Ginard D, Ricart E. Ginard D, et al. Gastroenterol Hepatol. 2009 Oct;32 Suppl 2:1-2. doi: 10.1016/S0210-5705(09)72597-X. Gastroenterol Hepatol. 2009. PMID: 19900620 Spanish. No abstract available.
Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study.
Nunes T, Barreiro-de Acosta M, Nos P, Marin-Jiménez I, Bermejo F, Ceballos D, Iglesias E, Gomez-Senent S, Torres Y, Ponferrada A, Arevalo JA, Hernandez V, Calvet X, Ginard D, Monfort D, Chaparro M, Manceñido N, Domínguez-Antonaya M, Villalón C, Perez-Calle JL, Muñoz C, Nuñez H, Carpio D, Aramendiz R, Bujanda L, Estrada-Oncins S, Hermida C, Barrio J, Casis MB, Dueñas-Sadornil MC, Fernández L, Calvo-Cenizo MM, Botella B, de Francisco R, Ayala E, Sans M; RECLICU Study Group of GETECCU. Nunes T, et al. Among authors: ginard d. J Crohns Colitis. 2010 Dec;4(6):629-36. doi: 10.1016/j.crohns.2010.07.003. J Crohns Colitis. 2010. PMID: 21122572
Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
González-Lama Y, Bermejo F, López-Sanromán A, García-Sánchez V, Esteve M, Cabriada JL, McNicholl AG, Pajares R, Casellas F, Merino O, Carpio D, Vera MI, Muñoz C, Calvo M, Benito LM, Bujanda L, García-Fernández FJ, Ricart E, Ginard D, Velasco M, Carneros JA, Manceñido N, Calvo M, Algaba A, Froilan C, Cara C, Maté J, Abreu L, Gisbert JP; "Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)". González-Lama Y, et al. Among authors: ginard d. Aliment Pharmacol Ther. 2011 Sep;34(5):544-54. doi: 10.1111/j.1365-2036.2011.04756.x. Epub 2011 Jul 3. Aliment Pharmacol Ther. 2011. PMID: 21722149
Does smoking influence Crohn's disease in the biologic era? The TABACROHN study.
Nunes T, Etchevers MJ, Merino O, Gallego S, García-Sánchez V, Marín-Jiménez I, Menchén L, Barreiro-de Acosta M, Bastida G, García S, Gento E, Ginard D, Gomollón F, Arroyo M, Monfort D, García-Planella E, Gonzalez B, Loras C, Agustí C, Figueroa C, Sans M; TABACROHN Study Group of GETECCU, Spanish Working Group in Crohn's Disease and Ulcerative Colitis. Nunes T, et al. Among authors: ginard d. Inflamm Bowel Dis. 2013 Jan;19(1):23-9. doi: 10.1002/ibd.22959. Inflamm Bowel Dis. 2013. PMID: 22467185
High smoking cessation rate in Crohn's disease patients after physician advice--the TABACROHN Study.
Nunes T, Etchevers MJ, Merino O, Gallego S, García-Sánchez V, Marín-Jiménez I, Menchén L, Barreiro-de Acosta M, Bastida G, García S, Gento E, Ginard D, Martí E, Gomollón F, Arroyo M, Monfort D, García-Planella E, Gonzalez B, Loras C, Agustí C, Figueroa C, Sans M; TABACROHN Study Group of GETECCU. Nunes T, et al. Among authors: ginard d. J Crohns Colitis. 2013 Apr;7(3):202-7. doi: 10.1016/j.crohns.2012.04.011. Epub 2012 May 23. J Crohns Colitis. 2013. PMID: 22626507 Clinical Trial.
73 results